Y
Yukiko Tsuji
Researcher at Kyoto Prefectural University of Medicine
Publications - 29
Citations - 497
Yukiko Tsuji is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 23 publications receiving 364 citations.
Papers
More filters
Journal ArticleDOI
Clinicopathological features of neuropathy associated with lymphoma.
Minoru Tomita,Haruki Koike,Yuichi Kawagashira,Masahiro Iijima,Hiroaki Adachi,Jun Taguchi,Takenori Abe,Kazuya Sako,Yukiko Tsuji,Masanori Nakagawa,Fumio Kanda,Fusako Takeda,Masashiro Sugawara,Itaru Toyoshima,Naoko Asano,Gen Sobue +15 more
TL;DR: The clinical, electrophysiological and histopathological features of 32 patients with neuropathy associated with non-Hodgkin's lymphoma that were unrelated to complications resulting from treatment for lymphoma are characterized.
Journal ArticleDOI
Nerve ultrasound depicts peripheral nerve enlargement in patients with genetically distinct Charcot-Marie-Tooth disease
Yu-ichi Noto,Kensuke Shiga,Yukiko Tsuji,Ikuko Mizuta,Yujiro Higuchi,Akihiro Hashiguchi,Hiroshi Takashima,Masanori Nakagawa,Toshiki Mizuno +8 more
TL;DR: Nerve US may aid in differentiating among the subtypes of CMT in combination with NCS, and in CMT1A, the median nerve CSA correlates with the disease severity and peripheral nerve function.
Journal ArticleDOI
Contrasting echogenicity in flexor digitorum profundus–flexor carpi ulnaris: A diagnostic ultrasound pattern in sporadic inclusion body myositis
Yu-ichi Noto,Kensuke Shiga,Yukiko Tsuji,Masaki Kondo,Takahiko Tokuda,Toshiki Mizuno,Masanori Nakagawa +6 more
TL;DR: FDP–FCU echogenicity contrast in muscle US is a sensitive diagnostic indicator of s‐IBM, but in none of those with PM/DM or ALS.
Journal ArticleDOI
A muscle ultrasound score in the diagnosis of amyotrophic lateral sclerosis.
TL;DR: Two or more of the fasciculation ultrasound scores showed high sensitivity and specificity in differentiating ALS patients from non-ALS patients, and can be a simple and useful diagnostic marker of ALS.
Journal ArticleDOI
A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Kazumoto Shibuya,Sonoko Misawa,Hideki Kimura,Yu Ichi Noto,Yasunori Sato,Yukari Sekiguchi,Yuta Iwai,Satsuki Mitsuma,Minako Beppu,Keisuke Watanabe,Yumi Fujimaki,Yukiko Tsuji,Toshio Shimizu,Toshiki Mizuno,Masanori Nakagawa,Kyoko Sawaguchi,Hideki Hanaoka,Satoshi Kuwabara +17 more
TL;DR: The results suggest that daily 300 mg mexiletine has no effects on axonal sodium current and ALSFRS-R deterioration in ALS, and there have to attempt another trial using a higher dose of mex toiletine or other agents to suppress sodium currents and ALS progression in the future.